Ovarian cancer staging: Does it require a gynecologic oncologist?

Allan R. Mayer, Setsuko K. Chambers, Ellen Graves, Carole Holm, Paul C. Tseng, Beth E. Nelson, Peter E. Schwartz

Research output: Contribution to journalArticlepeer-review

137 Scopus citations


Forty-seven patients with presumed Stages I-II invasive ovarian epithelial carcinoma were treated with intravenous 50 mg/m2cis-platinum, for 2-18 cycles (median, 9), 50 mg/m2 doxorubicin for 2-14 cycles (median, 9), and/or 600 mg/m2 cyclophosphamide for 2-14 cycles (median, 6) after surgical staging by a gynecologic oncologist or a nononcologic surgeon. Mean follow-up is 6.8 years. Cumulative 5-year actuarial survival is 73 ± 6%; 75 ± 12% for Stage I and 71 ± 8% for Stage II disease. When screened for poor prognosticators, only the specialty of the operating surgeon was identified (P < 0.05). Five-year actuarial survival and disease-free survival, respectively, for Stages I-II patients surgically staged by a gynecologic oncologist were 83 ± 7% and 76 ± 8%, compared to 59 ± 11% (P < 0.05) and 39 ± 11% (P < 0.03) for the group operated upon by a nononcologist.

Original languageEnglish (US)
Pages (from-to)223-227
Number of pages5
JournalGynecologic oncology
Issue number2
StatePublished - Nov 1992

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology


Dive into the research topics of 'Ovarian cancer staging: Does it require a gynecologic oncologist?'. Together they form a unique fingerprint.

Cite this